In a significant move that promises to reshape the landscape of metabolic health, Precision Diabetes, Inc. has announced an exclusive commercialization partnership with Austria-based biotechnology firm DirectSens. The collaboration focuses on bringing the MetMark clinical test—a diagnostic tool designed to measure alpha-hydroxybutyrate (AHB)—to the United States market. By leveraging DirectSens’ proprietary XpressGT enzymatic assay technology, this partnership aims to identify metabolic dysfunction long before it manifests as clinical type 2 diabetes (T2D).
The deal grants Precision Diabetes exclusive rights to market, sell, and distribute the XpressGT assay across the US for specific laboratory-developed test (LDT) applications related to diabetes and prediabetes. This strategic alignment combines DirectSens’ cutting-edge biochemical engineering with Precision Diabetes’ established expertise in clinical diagnostics and regulatory navigation.
The Science of Early Detection: What is AHB?
Alpha-hydroxybutyrate (AHB), also known as 2-hydroxybutyrate (2-HB), is a metabolic byproduct that has emerged as a high-value biomarker for early-stage metabolic stress. While traditional clinical practice has long relied on metrics such as fasting plasma glucose and HbA1c to monitor diabetes risk, these measures often fail to detect early insulin resistance or the initial decline in metabolic flexibility.
AHB serves as a subtle indicator of metabolic imbalance. Research suggests that elevated levels of AHB in the blood correlate with impaired glucose regulation and the early stages of insulin resistance. Because it can signal metabolic dysfunction before traditional markers become abnormal, AHB is positioned as a "leading indicator" rather than a lagging one.
Chronology of the Partnership and Scientific Validation
The momentum behind this partnership is not accidental; it is the culmination of years of rigorous clinical research and technological refinement.
2021: Establishing Intellectual Property
The foundation for this initiative was laid in 2021 when North Carolina-based Precision Diabetes acquired and issued a key patent covering the use of AHB as a biomarker. This patent specifically addressed the detection of elevated one-hour glucose levels during an oral glucose tolerance test (OGTT), providing a regulatory and commercial framework for the company’s future diagnostic products.
2026: A Year of Clinical Breakthroughs
The year 2026 proved to be the pivotal turning point for the validation of AHB as a viable clinical tool. Two major studies conducted throughout the year provided the necessary clinical evidence to move from the laboratory to the commercial sector.
- The Prospective Longitudinal Study: A significant prospective study tracking 1,349 participants over a decade demonstrated a robust link between baseline AHB levels and the development of T2D. Crucially, the researchers found that higher AHB levels remained an independent predictor of disease even after adjusting for traditional clinical risk factors, such as age, body mass index (BMI), and family history.
- The XpressGT Validation Study: A separate study assessed the efficacy of the DirectSens XpressGT assay specifically. The findings were striking: the assay successfully identified postprandial dysglycaemia (abnormal blood sugar levels after eating) in individuals whose fasting glucose and HbA1c results were otherwise within the "normal" clinical range.
How the Technology Works: The XpressGT Platform
The commercial viability of the MetMark test rests on the technical prowess of the DirectSens XpressGT assay. Designed for versatility, the XpressGT is an enzymatic assay capable of measuring AHB in serum or plasma samples.
Unlike experimental or niche diagnostic tools that require bespoke, expensive equipment, the XpressGT is engineered for compatibility. It can be integrated into standard, high-throughput clinical chemistry analyzers already found in most hospital and commercial diagnostic laboratories. This "plug-and-play" capability is essential for clinical adoption, as it allows medical professionals to incorporate AHB testing into routine laboratory workflows without requiring new infrastructure investments.
Under the terms of the agreement, DirectSens will handle the technical backbone of the rollout, supplying the assay technology, comprehensive product documentation, and the technical onboarding required to ensure that laboratories can run the test with high precision and reproducibility. Precision Diabetes will then take the reins for the commercial side, managing marketing, sales, laboratory implementation, and the complex process of securing reimbursement in the US healthcare environment.
Official Perspectives: The Vision for Preventive Medicine
The leadership at Precision Diabetes views this partnership as a fundamental shift in how the medical community approaches chronic disease.
Eric Button, founder and CEO of Precision Diabetes, emphasized the paradigm-shifting nature of the technology in a recent statement. "This is what makes AHB so compelling," Button noted. "AHB may allow us to identify increased metabolic risk years before diabetes becomes clinically apparent. The opportunity is not simply to diagnose disease earlier, but potentially to identify people while there is still time to intervene and change the trajectory."
By identifying patients in the "pre-diabetic" or "pre-pre-diabetic" window, clinicians can move beyond reactive care—which focuses on managing established hyperglycemia—toward proactive, personalized lifestyle interventions. This could include targeted dietary adjustments, exercise regimens, or early pharmacological support that may delay or even prevent the progression to full-blown type 2 diabetes.
Implications for the US Healthcare System
The introduction of the MetMark test into the US market has profound implications for public health, particularly in a country where the prevalence of type 2 diabetes continues to climb.
Bridging the Diagnostic Gap
Currently, millions of Americans exist in a state of "metabolic twilight." Their HbA1c levels may be in the high-normal range, and their fasting glucose may appear healthy, yet they are experiencing significant metabolic stress. The MetMark test offers a window into this hidden risk, providing a high-resolution view of how the body handles glucose processing.
Reducing the Economic Burden of T2D
Type 2 diabetes is one of the most expensive chronic conditions in the United States, consuming vast resources through long-term care, medication, and the treatment of severe complications like cardiovascular disease, neuropathy, and kidney failure. By shifting the focus to early detection and intervention, the adoption of AHB testing could theoretically reduce the long-term economic burden on both private insurers and public programs like Medicare and Medicaid.
Empowering Clinical Decision-Making
For the primary care physician, the MetMark test provides a data-driven tool to justify early intervention. It moves the conversation with patients away from vague warnings about "eating better" and toward concrete, biomarker-backed discussions about metabolic health. This objective data is a powerful motivator for patient compliance and behavioral change.
Future Outlook: Integrating AHB into Clinical Practice
As Precision Diabetes prepares for the commercial launch of the MetMark test, the company faces the challenge of clinical education. While the data from 2026 is compelling, the success of any new biomarker relies on the willingness of the medical community to adopt it into the standard of care.
The partnership with DirectSens, however, provides a strong tailwind. By utilizing existing clinical chemistry analyzers, the barrier to entry for laboratories is significantly lowered. Furthermore, the focus on reimbursement will be a critical factor in ensuring that patients have access to this testing without prohibitive out-of-pocket costs.
As the industry looks ahead, the integration of AHB testing may become a cornerstone of personalized metabolic management. If the MetMark test can successfully transition from clinical study to daily laboratory use, it could signal the beginning of a new era in which type 2 diabetes is treated not as an inevitable consequence of aging or genetics, but as a manageable, and perhaps preventable, metabolic state.
Conclusion
The alliance between Precision Diabetes and DirectSens marks a strategic marriage of clinical insight and diagnostic innovation. By providing the tools to detect metabolic dysfunction years before clinical symptoms arise, the MetMark test stands at the forefront of a shift toward true preventive medicine. With the scientific validation of AHB as a key biomarker now firmly established, the focus turns to the practical implementation of this technology across the US. As the healthcare industry continues to prioritize outcomes-based care, tools like the XpressGT assay may well become essential components in the quest to curb the global diabetes epidemic.
About the Author
